← Evidence map

ArticlePloS one2013

The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.

Karen Schneider et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2013

2014

2015

2016

2017

2018

2019

2020

this papercites it

The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa. | OpenQuestion